Guido Finazzi Selected Research

Essential Thrombocythemia

1/2019	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.
1/2018	Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
1/2018	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.
2/2017	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
10/2014	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
10/2014	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.
1/2014	Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.
7/2013	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
9/2012	Front-line therapy in polycythemia vera and essential thrombocythemia.
9/2011	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guido Finazzi Research Topics

Disease

32	Polycythemia Vera 12/2019 - 01/2003
28	Thrombosis (Thrombus) 01/2022 - 01/2003
18	Essential Thrombocythemia 01/2019 - 05/2003
16	Neoplasms (Cancer) 01/2020 - 08/2007
9	Primary Myelofibrosis (Myelosclerosis) 01/2018 - 01/2003
8	Venous Thrombosis (Deep-Vein Thrombosis) 11/2018 - 08/2007
5	Hemorrhage 11/2018 - 01/2008
5	Polycythemia (Erythrocytosis) 09/2012 - 01/2003
4	Anemia 01/2020 - 01/2003
4	Thrombocytosis (Thrombocythemia) 11/2018 - 09/2006
3	Stroke (Strokes) 11/2018 - 01/2003
3	Venous Thromboembolism 01/2018 - 03/2008
3	Splenomegaly 01/2018 - 02/2011
3	Fibrosis (Cirrhosis) 02/2014 - 05/2009
2	Leukocytosis (Pleocytosis) 11/2018 - 03/2007
2	Pulmonary Embolism 01/2018 - 03/2016
1	Staphylococcal Food Poisoning 12/2020
1	Foodborne Diseases 12/2020
1	Second Primary Neoplasms (Neoplasms, Second) 01/2020
1	Skin Neoplasms (Skin Cancer) 01/2019
1	Transient Ischemic Attack 01/2018
1	Clinical Deterioration 01/2018
1	Liver Diseases (Liver Disease) 01/2018
1	Ischemic Stroke 01/2018
1	Leukemia 10/2014
1	Thrombophilia 12/2013
1	Thromboembolism 10/2012
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2012
1	Hypertension (High Blood Pressure) 06/2012
1	Philadelphia Chromosome 05/2012
1	Portal Hypertension 02/2011
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 02/2011
1	Inflammation (Inflammations) 02/2011
1	Atrial Fibrillation 10/2009
1	Hyperplasia 05/2009
1	Acute Coronary Syndrome 03/2008
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2008
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 08/2007
1	Disease Progression 03/2007

Drug/Important Bio-Agent (IBA)

17	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2020 - 05/2003
17	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 01/2003
5	ruxolitinibIBA 01/2020 - 02/2017
5	AnticoagulantsIBA 01/2019 - 08/2007
4	Hemoglobins (Hemoglobin)IBA 01/2018 - 07/2012
4	Thrombin FDA Link 03/2016 - 04/2011
4	givinostatIBA 06/2013 - 08/2010
3	Vitamin K FDA Link 01/2018 - 03/2008
3	Janus Kinase 2IBA 10/2014 - 08/2007
3	Reticulin (Reticular Fiber)IBA 02/2014 - 05/2009
3	Histone Deacetylase InhibitorsIBA 06/2013 - 08/2010
2	Thromboxane B2IBA 01/2018 - 09/2006
2	CalreticulinIBA 10/2014 - 10/2014
2	Antiphospholipid AntibodiesIBA 06/2012 - 08/2007
2	Warfarin (Coumadin)FDA LinkGeneric 10/2009 - 08/2007
1	Surface Antigens (Surface Antigen)IBA 01/2022
1	CollagenIBA 01/2022
1	spleen fibrinolytic proteinase (human) (SFP)IBA 12/2020
1	Pipobroman (Vercyte)FDA Link 01/2019
1	Drug CombinationsIBA 01/2019
1	Syntex adjuvant formulationIBA 01/2017
1	apixabanIBA 03/2016
1	Factor Xa (Coagulation Factor Xa)IBA 03/2016
1	RivaroxabanIBA 03/2016
1	Dabigatran FDA Link 03/2016
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2014
1	Protein CIBA 12/2013
1	Adenosine Diphosphate (ADP)IBA 07/2013
1	Purinergic P2 Receptors (ADP Receptor)IBA 07/2013
1	Transcription Factors (Transcription Factor)IBA 08/2012
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 06/2012
1	Everolimus FDA Link 08/2011
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2011
1	AndrogensIBA 02/2011
1	HematinicsIBA 02/2011
1	Immunologic Factors (Immunomodulators)IBA 02/2011
1	PTX3 proteinIBA 02/2011
1	C-Reactive ProteinIBA 02/2011
1	Histone Deacetylases (Histone Deacetylase)IBA 08/2010
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 03/2008
1	AnnexinsIBA 08/2007
1	AntibodiesIBA 08/2007
1	Prothrombin (Factor II)IBA 08/2007
1	APTIBA 08/2007
1	beta 2-Glycoprotein I (Apolipoprotein H)IBA 08/2007
1	Immunoglobulin M (IgM)IBA 08/2007
1	Immunoglobulin G (IgG)IBA 08/2007
1	Anticardiolipin AntibodiesIBA 08/2007
1	Protein SIBA 08/2007
1	beta-ThromboglobulinIBA 09/2006
1	Phosphotransferases (Kinase)IBA 09/2006
1	Platelet Factor 4IBA 09/2006
1	von Willebrand FactorIBA 09/2006

Therapy/Procedure

20	Therapeutics 01/2020 - 01/2003
2	Renal Dialysis (Hemodialysis) 10/2012 - 10/2009
2	Drug Therapy (Chemotherapy) 08/2007 - 01/2003
1	Liver Transplantation 01/2018
1	Stem Cell Transplantation 01/2018
1	Splenectomy 02/2011
1	Contraindications 10/2009
1	Operative Surgical Procedures 01/2008